Malignant Female Reproductive System Neoplasm
NCI Definition: A primary or metastatic malignant neoplasm involving the female reproductive system. Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumor, and gestational choriocarcinoma. 
Malignant female reproductive system neoplasms most frequently harbor alterations in TP53, PIK3CA, PTEN, ARID1A, and KRAS .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, PIK3CA Mutation, and PTEN Mutation are the most common alterations in malignant female reproductive system neoplasm .
There is 1 clinical trial for malignant female reproductive system neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains malignant female reproductive system neoplasm as an inclusion criterion, 1 is phase 1/phase 2 (1 open).
Lucitanib and nivolumab are the most common interventions in malignant female reproductive system neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.